Skip to main content
Congenital fibrinogen deficiency patient Emily Bartko and her mom.)

For Patients

Our Promise to Patients

At CSL we are Driven by Our Promise and guided by our Values: Patient Focus, Innovation, Integrity, Collaboration and Superior Performance.

CSL is committed to putting the patient first in all that we do to discover, develop, and deliver biotherapeutics and vaccines that meet their needs.

We know that every patient is someone’s child, parent, grandparent, family member, friend or colleague. We also understand that rare and serious diseases impact more than just the patient. They also impact their loved ones and the communities that support them.

With that in mind, we strive to deliver therapeutics that meet patient needs, as well as build support systems to create empowerment and community through various programs and activities around the world. We also partner with patient advocacy organizations to improve and expand outreach, education and access to medicines and resources.

Our patients are our passion and that drives the way we work. We are committed to full transparency of expectations and outcomes when partnering with them. We listen closely to patients about their experiences and collaborate with them from early research through the delivery of our innovative medicines. We seek to fully understand their challenges to ensure our research is relevant, meaningful and leads to therapies that result in outcomes that are important to them and make a difference in their lives.

Our people are the heart of our Patient Focus culture and we strive to earn our patients’ trust every day. CSL employees understand that they are personally accountable for ensuring our interactions with patients are responsible, respectful and humble. We recognize patients as the experts in how diseases impact their lives and we actively seek their insights to guide our efforts.

The commitment of our people to Patient Focus as part of our Values-based culture is essential to delivering on our promise to patients and improving public health.

Bottles on assembly line

CSL’s Response to COVID-19

Despite the constantly challenging environment the COVID-19 pandemic has presented to the world, CSL has remained steadfast in our promise to safeguarding our patients, our plasma donors and our employees. As the pandemic continues to evolve, so have we. CSL has redirected resources and taken on extra commitments to protect public health where we could offer the most value, including our expertise, technologies, equipment and materials. And through it all, we continue to deliver on our promise for those who need us most, our patients.

Read More About CSL Behring's Efforts with COVID-19

How can we help you?

Immunodeficiency & Autoimmune Diseases

We offer one of the most comprehensive portfolios of high-quality, technically advanced immunoglobulin (Ig) therapies and we are the leading Ig manufacturer in the world. Treatments are available for the following conditions:

Hereditary Bleeding Disorders

We are a world leader in innovative medicines for the treatment of bleeding disorders. We offer the largest portfolio for the treatment of hereditary bleeding disorders with more than a dozen plasma-derived and recombinant coagulation factor concentrates. Treatments are available for the following conditions:

Hereditary Angioedema (HAE)

We introduced the world's first subcutaneous preventative treatment for attacks of Hereditary Angioedema (HAE), while still offering our intravenous C1-esterase inhibitor therapy for on-demand treatment.

Alpha 1 Antitrypsin Deficiency

Our Alpha 1 Antitrypsin treats Alpha 1 Antitrypsin Deficiency (AATD) in patients with AATD-related emphysema.

Smith family at a picnic Smith family at a picnic

" Get involved. There are tips and tricks other parents learn over the years in raising children with rare disease. Getting that first-hand advice is helpful. "

- Madonna McGuire-Smith, mother of children with hemophilia

Find a Clinical Trial

A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants."

Therapeutic Area Condition Study
Number 
Description Status
(Click on link to learn more)
Haematology and Thrombosis
Sickle Cell CSL889_1001          A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease  Recruiting 
  Hemophilia A OPERA
Register of Patients With haEmophilia A tReated With Afstyla® (OPERA)
Recruiting 
  Von Willebrand Disease OPALE Registry of Patients With Von WilLEbrand Disease Treated With Voncento® (OPALE)  Recruiting 
Cardiovascular and Metabolic Acute Coronary Syndrome CSL112_3001 Study to investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) Recruiting
  Diabetic Kidney Disease            CSL346_2001 A Phase 2a Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease             Recruiting           
Immunology and Neurology Dermatomyositis (DM) IgPro20_3007 A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with Dermatomyositis (DM) Recruiting
  Pediatric CIDP IgPro10_4002 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting
  Hereditary Angioedema (HAE) CSL312_2001 A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) Active, Not Recruiting

Hereditary Angioedema (HAE)
CSL312_3001 CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
Recruiting
  Hereditary Angioedema (HAE)
CSL312_3002 Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks Recruiting
  Hidradenitis Suppurativa and Palmoplantar Pustulosis CSL324_1002 A study of the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis Recruiting
  Inflammatory Neuropathy pHeNIx Hizentra® in Inflammatory Neuropathies - pHeNIx Study
Suspended

Systemic Sclerosis IgPro20_2001 A study to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in subjects with diffuse cutaneous systemic sclerosis (dcSSc) Active, Not Recruiting
  Healthy Subjects CSL324_1003 Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects Recruiting
  Healthy Subjects CSL730_1002 A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects  Recruiting
Respiratory Mild Asthma CSL311_1001 A Clinical Study to test the safety, exposure, and markers of Efficacy of CSL311 in patients with mild asthma. Active, Not Recruiting
  alpha-1 antitrypsin deficiency  AmAREtTI Study  Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage)  Recruiting 
  Non-cystic Fibrosis Bronchiectasis (NCFB) CSL787_1001 Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)  Recruiting
Transplant            Antibody-mediated kidney transplant rejection  CSL300_3001  A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients  Recruiting 
  Acute GVHD (aGVHD) CSL964_2001 The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE) Recruiting
  Graft Versus Host Disease (GVHD) CSL964_5001 A study on the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD Recruiting

 

COMPLETED STUDIES:

COVID-19 COVID-19 CSL312_COVID-19  A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)   Completed
  COVID-19 CSL324_COVID-19 CSL324 in COVID-19 Withdrawn
  COVID-19 CSL760_1001  Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects Cancelled
Haematology and Thrombosis
Reversal of acquired coagulation factor deficiency
BE1116_4001
An Observational Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding
Completed

Congenital Fibrinogen Deficiency  BI3023_4003  An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency Completed
  Sickle Cell  CSL200_1001 
CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
Cancelled
  Hemophilia A CSL627_3001   An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A  Completed
  Hemophilia B
CSL654_3003
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
Completed
  Von Willebrand Disease CSLCT-BIO-12-83 Study of Voncento® in Subjects With Von Willebrand Disease  Completed
Cardiovascular and Metabolic Coronary Heart Disease CSL112_1001 Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults Completed
Renal Impairment and Acute Myocardial Infarction (AMI) CSL112_2001 A Phase 2 Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Moderate Renal Impairment and Acute Myocardial Infarction Results
  Acute Myocardial Infarction (AMI)  CSLCT-HDL-12-77  A Phase 2b study to investigate the hepatic and renal safety and tolerability of multiple dose administration of two dose levels of CSL112 compared with placebo in subjects with acute myocardial infarction (AMI)
Results
Immunology and Neurology
Hereditary Angioedema (HAE)

CSL830_2001

A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route
Results
  Hereditary Angioedema (HAE)
CSL830_3001 A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
Results
  Hereditary Angioedema (HAE)
CSL830_3002 A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
Results 
  Hereditary Angioedema (HAE)
CSL830_3003 A Phase 3 study to evaluate clinical efficacy, safety, and pharmacokineti00cs of subcutaneous administration of human plasma derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema in Japanese subjects 
Results

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IgPro20_3004 Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Results
  Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IgPro10_5004 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1) Cancelled
  HIV-1 CAL-USA-11 An Adaptive Phase I/II Study of the Safety of CAL-USA-11 in HIV-1 Infected Adults Previously Exposed to ART Results
  Primary Immune Deficiency (PID) IgPro20_1001 Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump  Results
  Primary Immune Deficiency (PID) IgPro20_4004 Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID) Results
  Primary Immune Deficiency (PID) IgPro20_4005 Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Results
  Systemic Sclerosis IgPro10_2001  Efficacy and safety study of IgPro10 in adults with Systemic Sclerosis  Withdrawn
  Health Subjects CSL312_1003 A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults Completed
  Healthy Subjects CSL324_1001  Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Completed
  Healthy Subjects CSL730_1001 Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults  Cancelled 
Transplant  Antibody-mediated kidney transplant rejection CSL842_3001  Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients  Cancelled

Participate in a Clinical Trial

Discover what is involved in participating in one of our clinical trials and how you can enroll.

Learn More